Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dor BioPharma has signed a letter of intent with BL&H Co., a specialty pharmaceutical company based in Seoul, South Korea, pursuant to which BL&H will act as Dor's sponsor with regard to the administration of a Named Patient Program for orBec to patients suffering from acute gastrointestinal graft-versus-host disease in South Korea.
Subscribe to our email newsletter
The NPP is a compassionate use drug supply program administered by the Korea Orphan Drug Center (KODC) under which medical practitioners can legally supply investigational drugs to their patients who qualify. Under this program, investigational drugs can be administered through KODC to patients who are suffering from serious illnesses until the drug is approved by the Korea Food & Drug Administration. BL&H and Dor will share revenues generated by sales of orBec through the NPP. Dor will manufacture and supply orBec to BL&H, while BL&H will be responsible for all distribution costs in South Korea.
Christopher Schaber, president and CEO of Dor BioPharma, said: “We will continue to pursue similar types of programs in the US, Europe and the rest of the world so that GI GVHD patients will have this important treatment option.”